Karim Gariani

Dr. Karim Gariani

1. Service of Endocrinology, Diabetes, Hypertension and Nutrition, Geneva University Hospitals, Rue Gabrielle-Perret-Gentil 4, 1205 Geneva, Switzerland
+1
orcid

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 June 2023 in Frontiers in Endocrinology
Verified
Journal Article
Open access
SWShibo Wei
Shibo Wei
TNThanh T. Nguyen
Thanh T. Nguyen
YZYan Zhang
Yan Zhang
DRDongryeol Ryu
Dongryeol Ryu
KGKarim Gariani
Karim Gariani
Sarcopenic obesity is defined as the coexistence of sarcopenia and obesity in the same individual, characterized by of the co-presence of body fat accumulation and muscle loss. This condition is currently a major concern as it is associated with frailty and disabilities such as cardiovascular disease, fractures, dementia, cancer, and increased all-cause mortality. Particularly, older individuals remain at risk of sarcopenic obesity. Progress at several levels is needed to improve the global prognostic outlook for this condition, including the elaboration and implementation of a more uniform definition that may favor the identification and specification of prevalence by age group. Furthermore, improvements in the understanding of the pathogenesis of sarcopenic obesity may lead to the development of more specific therapeutic interventions to improve prognosis. We reviewed the knowledge on sarcopenic obesity and its associations with cardiovascular diseases and mortality.

29 March 2023 in Journal of Cellular and Molecular Medicine
Verified
Journal Article
Open access
MAMohamed Asrih
Mohamed Asrih
SWShibo Wei
Shibo Wei
TNThanh T. Nguyen
Thanh T. Nguyen
HYHyon‐Seung Yi
Hyon‐Seung Yi
Dongryeol RyuDongryeol Ryu
Dongryeol Ryu
KGKarim Gariani
Karim Gariani
Growth and differentiation factor 15 (GDF15) is a member of the transforming growth factor‐β (TGF‐β) superfamily. GDF15 has been linked with several metabolic syndrome pathologies such as obesity and cardiovascular diseases. GDF15 is considered to be a metabolic regulator, although its precise mechanisms of action remain to be determined. Glial cell‐derived neurotrophic factor family receptor alpha‐like (GRAL), located in the hindbrain, has been identified as the receptor for GDF15 and signals through the coreceptor receptor tyrosine kinase (RET). Administration of GDF15 analogues in preclinical studies using various animal models has consistently been shown to induce weight loss through a reduction in food intake. GDF15, therefore, represents an attractive target to combat the current global obesity epidemic. In this article, we review current knowledge on GDF15 and its involvement in metabolic syndrome.

1 March 2016 in European Journal of Internal Medicine
Verified
Journal Article
Closed access
KGKarim Gariani
Karim Gariani
TMThomas Mavrakanas
Thomas Mavrakanas
CCChristophe Combescure
Christophe Combescure
APArnaud Perrier
Arnaud Perrier
CMChristophe Marti
Christophe Marti

17 January 2024 in Frontiers in Endocrinology
Verified
Journal Article
Open access
FWFelix W. A. Waibel
Felix W. A. Waibel
IUIlker Uçkay
Ilker Uçkay
LSLaura Soldevila-Boixader
Laura Soldevila-Boixader
CSChristina Sydler
Christina Sydler
KGKarim Gariani
Karim Gariani
Diabetes is a chronic disease associated with numerous complications including diabetic foot disorders, which are associated with significant morbidity and mortality as well as high costs. The costs associated with diabetic foot disorders comprise those linked to care (direct) and loss of productivity and poor quality of life (indirect). Due to the constant increase in diabetes prevalence, it is expected that diabetic foot disorder will require more resources, both in terms of caregivers and economically. We reviewed findings on management, morbidity, mortality, and costs related to diabetic foot disorder.

9 June 2022 in Antioxidants
Verified
Journal Article
Open access
PDF file
ANAlberto Nascè
Alberto Nascè
KGKarim Gariani
Karim Gariani
Francois Roland JornayvazFrancois Roland Jornayvaz
Francois Roland Jornayvaz
Ildiko SzantoIldiko Szanto
Ildiko Szanto
Nonalcoholic fatty liver disease (NAFLD), characterized by ectopic fat accumulation in hepatocytes, is closely linked to insulin resistance and is the most frequent complication of type 2 diabetes mellitus (T2DM). One of the features connecting NAFLD, insulin resistance and T2DM is cellular oxidative stress. Oxidative stress refers to a redox imbalance due to an inequity between the capacity of production and the elimination of reactive oxygen species (ROS). One of the major cellular ROS sources is NADPH oxidase enzymes (NOX-es). In physiological conditions, NOX-es produce ROS purposefully in a timely and spatially regulated manner and are crucial regulators of various cellular events linked to metabolism, receptor signal transmission, proliferation and apoptosis. In contrast, dysregulated NOX-derived ROS production is related to the onset of diverse pathologies. This review provides a synopsis of current knowledge concerning NOX enzymes as connective elements between NAFLD, insulin resistance and T2DM and weighs their potential relevance as pharmacological targets to alleviate fatty liver disease.

30 August 2024 in Frontiers in Endocrinology
Verified
Journal Article
Open access
PDF file
EJEun-Ju Jin
Eun-Ju Jin
YJYunju Jo
Yunju Jo
SWShibo Wei
Shibo Wei
MRManfredi Rizzo
Manfredi Rizzo
Dongryeol RyuDongryeol Ryu
Dongryeol Ryu
KGKarim Gariani
Karim Gariani
Diabetes mellitus is a complex chronic disease, considered as one of the most common metabolic disorders worldwide, posing a major threat to global public health. Ferroptosis emerges as a novel mechanism of programmed cell death, distinct from apoptosis, necrosis, and autophagy, driven by iron-dependent lipid peroxidation accumulation and GPx4 downregulation. A mounting body of evidence highlights the interconnection between iron metabolism, ferroptosis, and diabetes pathogenesis, encompassing complications like diabetic nephropathy, cardiomyopathy, and neuropathy. Moreover, ferroptosis inhibitors hold promise as potential pharmacological targets for mitigating diabetes-related complications. A better understanding of the role of ferroptosis in diabetes may lead to an improvement in global diabetes management.In this review, we delve into the intricate relationship between ferroptosis and diabetes development, exploring associated complications and current pharmacological treatments.